MelaRisk-001: validation of a 7-marker IHC assay in stage IB/IIA cutaneous melanoma

Teresa Amaral, MD, PhD, University of Tübingen, Tübingen, Germany, discusses the multicenter MelaRisk-001 study (NCT05933577), which assessed a prognostic 7-marker immunohistochemistry (7-IHC) assay for stage IB/IIA cutaneous melanoma (CM). This study aims to identify high or low recurrence risk in patients using primary tumor assays involving immunohistochemistry (IHC) and gene expression profiling. These assays could be used with or without sentinel lymph node biopsy data. This is crucial as current adjuvant treatments are given without specific biomarkers, risking unnecessary toxicity and costs. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.